A leading Chinese COVID-19 vaccine developed by Sinovac Biotech was just 50.38% effective in late-stage trials in Brazil, significantly lower than earlier results showed, according to a statement published by the government of Sao Paulo Tuesday.While the number exceeds the threshold required for regulatory approval, it falls far below the , raising questions as to the veracity of the data and fueling skepticism over the apparent lack of transparency regarding .Analysts said the efficacy rate of Sinovac's Coronavac vaccine in Brazil -- the lowest among its global competitors -- could affect...…A leading Chinese COVID-19 vaccine developed by Sinovac Biotech was just 50.38% effective in late-stage trials in Brazil, significantly lower than earlier results showed, according to a statement published by the government of Sao Paulo Tuesday.While the number exceeds the threshold required for regulatory approval, it falls far below the , raising questions as to the veracity of the data and fueling skepticism over the apparent lack of transparency regarding .Analysts said the efficacy rate of Sinovac's Coronavac vaccine in Brazil -- the lowest among its global competitors -- could affect...WW…